control viremia prevention clinical aids rhesus monkeys cytokine-augmented dna vaccination
accumulating evidence indicating importance cytotoxic t lymphocytes ctls containing human immunodeficiency virus hiv- replication infected individuals strategies pursued elicit virus-specific ctls prototype hiv vaccines report protective efficacy vaccine-elicited immune responses pathogenic shiv-6p challenge rhesus monkeys immune responses elicited dna vaccines expressing sivmac239 gag hiv 6p env augmented administration purified fusion protein il-/ig consisting interleukin il- fc portion immunoglobulin g igg plasmid encoding il-/ig shiv-6p infection sham-vaccinated monkeys developed weak ctl responses rapid loss cd4+ t cells virus-specific cd4+ t cell responses high setpoint viral loads significant clinical disease progression death half animals day challenge contrast monkeys received dna vaccines augmented il-/ig infected demonstrated potent secondary ctl responses stable cd4+ t cell counts preserved virus-specific cd4+ t cell responses low undetectable setpoint viral loads evidence clinical disease mortality day challenge
